Immunoassay Interference Reduction via Label Masking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Immunoassays face interference issues due to non-specific binding of assay components to solid phases and the presence of interfering factors like anti-label antibodies, leading to false-positive or false-negative results and reduced sensitivity.
Innovation Solution
Incorporating a label-specific binding partner, a biological molecule composed of amino acids, which binds to the detectable label without carrying a label itself, to shield the label from interfering compounds and prevent non-specific binding, thereby enhancing assay specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a detectable label is used in the immunoassay, then the assay sensitivity and detection capability are improved, but non-specific binding of interfering compounds to the label causes false-positive or false-negative results
Solution Approach 1:
A label-specific binding partner (LSBP) is introduced as an intermediary component that binds to the detectable label. This LSBP acts as a protective mediator that prevents interfering compounds from binding directly to the label, thereby eliminating non-specific interference while preserving the label's detection function. The LSBP competes with interfering compounds for binding sites on the label, ensuring specific interaction.
Solution Approach 2:
The label-specific binding partner is added to the assay mixture before the detection step to preemptively block interfering compounds from binding to the label. By establishing this protective binding in advance, the assay prevents false-positive or false-negative results that would otherwise occur during the detection phase.
2Object-affected harmful factors
If blocking agents are used to prevent non-specific binding, then interference is reduced, but assay complexity and reagent requirements increase
Solution Approach 1:
The label-specific binding partner serves multiple functions simultaneously: it blocks non-specific binding of interfering compounds to the label, maintains assay sensitivity, and can be used across different immunoassay formats. This multi-functionality reduces the need for multiple separate blocking agents and simplifies the overall assay design.
3Object-affected harmful factors
If excess carrier protein is added to reduce interference with signal-generating components, then non-specific binding is reduced, but reagent cost and assay complexity increase
Solution Approach 1:
Instead of adding excess carrier protein, the invention uses a label-specific binding partner as a targeted intermediary that specifically binds to the signal-generating label. This approach provides interference reduction with precise stoichiometric control, avoiding the need for large excesses of reagents.
4Object-affected harmful factors
If similar but non-binding compounds are added to compete with interfering factors, then interference is reduced, but assay sensitivity and signal strength decrease
Solution Approach 1:
The label-specific binding partner serves as a selective intermediary that binds to the label without preventing the label's signal-generating function. Unlike competing compounds that may block the label's active sites, the LSBP binds to a different site on the label, maintaining both interference blocking and signal detection capabilities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces interference, maintaining assay sensitivity and specificity by masking the label and blocking potential binding sites for interfering compounds, allowing for accurate detection of analytes even in the presence of anti-label antibodies.
Implementation Method 1
a label-specific binding partner is added that does not carry a label but binds to said detectable label
Data Source
Figure 1a
Figure 1b
Figure 2
AI summary
The invention concerns an immunoassay method for detecting an analyte such as an antigen or an antibody in an isolated sample suspected to contain said analyte by incubating said sample with a plurality of binding partners, one of which carries a detectable label, wherein a label-specific binding partner is added that does not carry a label but binds to said detectable label. The method is applicable for a large variety of analytes and has proven particularly useful for analyte antibodies of the IgG and IgM class present in samples due to infections by pathogens. The invention further concerns a reagent kit useful for said method comprising at least two analyte-specific binding partners one of which carries a detectable label and a label- specific binding partner that binds to said detectable label but itself does not carry a detectable label. In addition, the invention covers the use of a label-specific binding partner that does not carry a detectable label in an in vitro diagnostic test for eliminating interferences caused by anti-label antibodies present in a sample.